Under construction – not a live service
Sign in
Taking people in FranceNo phase

Dynamic PET Scans Before Lutetium Treatment in Metastatic Prostate Cancer

Compares two PET scan methods to find prostate cancer spread in adults.

Key facts

Who runs it
Centre Henri Becquerel
Where
Rouen, FranceSee the site
Trial code
Registry title
Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA
Status
Recruiting
People taking part
60 people, planned
Started
5 Mar 2025
Expected to end
5 Mar 2028
Type of study
Interventional
Treatments tested
  • Parametric acquisition
Record updated
2 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread, no longer responds to hormone-lowering treatment and keeps getting worse. They must be assessed with two PET/CT scans before a possible 177Lu-PSMA treatment.

Age
18 years or older
Sex
Men only
Disease stage
Metastatic castration-resistant prostate cancer (adenocarcinoma) that keeps progressing; WHO stage 0 or 1
Earlier treatment
Must have had taxane chemotherapy and at least one anti-androgen hormone therapy

Main reasons for not taking part

  • Cannot understand the study or follow its requirements
  • Cannot have the scans or lie still for a long time (for example because of back pain)

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Signed informed consent
  • Progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy
  • Evaluated by 18F-FDG and 68Ga-PSMA PET/CT prior to potential treatment with 177Lu-PSMA
  • Affiliated with or beneficiary of a social protection scheme
  • WHO stage 0 or 1

Who cannot take part

  • Patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.)
  • Patients unable to undergo the examinations and/or maintain a prolonged lying position (due to back pain, etc.)

Where in France

  • Centre Henri BecquerelRouen, FranceContact: Pierre Decazes, MdTaking people

About the trial

What the trial wants to find out

Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe.

Read full original descriptionShow less

The PSMA is a target for mCRPC treatment, with therapies like 177Lu-PSMA-617 delivering radiation to cancer cells. The Vision study showed that 177Lu-PSMA-617, combined with standard care, improved survival rates significantly compared to standard care alone.The French ANSM authorized 177Lu-PSMA-617 for mCRPC under certain conditions. Patients must have histologically confirmed mCRPC, be progressive despite treatment, and have PSMA-positive imaging.

Imaging assessments include PSMA PET/CT and 18F-FDG PET/CT to identify FDG-positive and PSMA-negative sites, which are associated with a poorer prognosis.

Parametric analysis using dynamic PET could improve lesion characterization, aiding in treatment decisions. This is the focus of the PyPET study.

The main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate Ki, volume of distribution Vd) and static analysis (standard at 1 hour) using 18F-FDG and 68Ga-PSMA PET/CT for diagnosing metastases, especially in the liver, lymph nodes, and bones. It aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.

The group in the trial

  • Dynamic and static acquisitionTreatment being tested

    Dynamic and static PET acquisitions with 18F-FDG and 68Ga-PSMA will be performed with a minimum of 24 hours and a maximum of 15 days between the two

    Treatment: Parametric acquisition

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis of Metastatic Prostatic Adenocarcinomas Prior to 177Lu-PSMA Treatment
Plain-language title
Dynamic PET Scans Before Lutetium Treatment in Metastatic Prostate CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 January 2026